About Us


time:04/27/2018 page views: resource:BioBAY

ChinaBio® Partnering Forum 2018 (CBPF2018), initiated by ChinaBio and EBD, and sponsored by BioBay, was successfully held in Suzhou from April 25 to 26, 2018. 

The forum attracted more than 800 participants, including high-level decision-makers of domestic and international companies such as Roche, AbbVie, Johnson & Johnson, Merck, Sanofi, Pfizer, Bayer, Novo Nordisk, Luoxin, Ascentage Pharma, Alphamab and Kintor, experts and scholars of finance, law, taxation, investment banks, industrial associations, scientific research institutions and universities. They gathered in Suzhou to explore the latest trends and future development of the Chinese and global biotech industry from the perspective of cooperation, innovation, and investment. EBD’s partneringONE® was introduced at the event to enable guests to hold one-on-one meetings with companies in the life science industrial chain, establish a mature conference ecological chain of early R&D, technological cooperation, investment and financing as well as create cooperation opportunities. 

It was the 5th session that CBPF held in Suzhou since 2009, introduced by BioBay in a bid to evoke thinking and development of the entire industry, exchanges and interaction of all links in the ecological chain. BioBay is committed to building a world-class bio-industrial ecosystem with focus on collaboration and cooperation. The park perfectly integrates global capital, technology, talents, and policies as well as other resources of all stakeholders, and strives to speed up concentration and development of innovative enterprises with a full range of industrial chains as attraction and outstanding industry leaders as the driving force. This conforms to the forum’s keynote and goal.

CBPF has become China’s leading life science conference and this year marks its 10th anniversary. In the past decade, China’s medicine and health industry has witnessed rapid development and it’s experiencing ongoing changes from a domestic to global perspective. The vibrant medical innovation, vigorous CFDA reform, a large number of elite returnees, and ample funds significantly increased the number and quality of biomedicine innovation enterprises. In the past year, total amount of investment in M&A and the life science sector doubled to US$65 billion, thanks to the strong capital market and the good news that Hong Kong Exchange and Clearing Limited (HKEX) intends to list unprofitable biopharm companies in Hong Kong. The capital market will bring greater support to innovation and development of the biopharm industry. 

The “SIP legion” is poised for greater development in the capital market. A total of 29 innovative biopharm enterprises in SIP are qualified for HKEX’s IPO green passage for non-revenue biopharm enterprises that will be opened soon, in addition to eight enterprises that are expected to meet such conditions in three years’ time. BioBay is building platforms through this forum to assemble and share industrial development resources and information, provide an exchange channel for enterprises and investors in SIP and industrial market players (investment banks, accountants, and lawyers among others.) to meet financing needs of innovative enterprises in different development phases as well as prepare SIP-based enterprises for financing through IPO. 

In more than 10 years of development, BioBay has been committed to building a world-class ecosystem of the biological industry with the attitude of “concentration, collaboration and creativity”. It has attracted more than 430 enterprises and more than 10,000 biopharm professionals, including 63 under the 1000-talent Plan. It has formed new drug discovery, medical device, biological technology and other competitive industrial clusters. With BioBay’s rapid development, 10 enterprises such as GenePharma, Xinhai and Synbio Technologies have listed on the New Third Board. Some enterprises have launched the overseas IPO plans. For example, BeiGene, Hutchison MediPharm and Zai Lab have successfully listed on NASDAQ, while Innovent Biologics, Ascentage Pharma, Alphamab and Kintor are preparing for IPOs in Hong Kong, and another 20 enterprises have completed or are preparing for the equity division reform.